British Journal of Cancer - Table of Contents alert Volume 118 Issue 1

If you are unable to see the message below, click here to view.

TABLE OF CONTENTS Volume 118, Issue 1 (January 2018) In this issue Editorial Minireview Review Clinical Studies Translational Therapeutics Molecular Diagnostics Genetics & Genomics Epidemiology Also new AOP   Sign up for e-alerts Recommend to your library Web feed Subscribe Editorial Cell and molecular biology: a new section joins the fight against cancer Colin R Goding British Journal of Cancer 2017 118: 1 - 2; December 12, 2017; 10.1038/bjc.2017.443   Abstract | Full Text Minireview Targeting the Raf kinases in human cancer: the Raf dimer dilemma David E Durrant & Deborah K Morrison British Journal of Cancer 2017 118: 3 - 8; December 14, 2017; 10.1038/bjc.2017.399   Abstract | Full Text Review Mechanisms of resistance to immune checkpoint inhibitors Russell W Jenkins, David A Barbie& Keith T Flaherty British Journal of Cancer 2018 118: 9 - 16; January 02, 2018; 10.1038/bjc.2017.434   Abstract | Full Text Clinical Studies Long-term survival outcomes of triple-receptor negative breast cancer survivors who are disease free at 5 years and relationship with low hormone receptor positivity S M Reddy, C H Barcenas, A K Sinha, L Hsu, S L Moulder et al. British Journal of Cancer 2017 118: 17 - 23; December 12, 2017; 10.1038/bjc.2017.379   Abstract | Full Text Variation in 'fast-track' referrals for suspected cancer by patient characteristic and cancer diagnosis: evidence from 670?000 patients with cancers of 35 different sites Y Zhou, S C Mendonca, G A Abel, W Hamilton, F M Walter et al. British Journal of Cancer 2017 118: 24 - 31; November 28, 2017; 10.1038/bjc.2017.381   Abstract | Full Text Standard-dose osimertinib for refractory leptomeningeal metastases in T790M-positive EGFR-mutant non-small cell lung cancer Shigeki Nanjo, Akito Hata, Chiyuki Okuda, Reiko Kaji, Hideaki Okada et al. British Journal of Cancer 2017 118: 32 - 37; November 30, 2017; 10.1038/bjc.2017.394   Abstract | Full Text Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC Shirish Gadgeel, Alice T Shaw, Fabrice Barlesi, Lucio Crinò, James Chih-Hsin Yang et al. British Journal of Cancer 2017 118: 38 - 42; November 16, 2017; 10.1038/bjc.2017.395   Abstract | Full Text Translational Therapeutics Targeting de novo lipogenesis as a novel approach in anti-cancer therapy Katharina Stoiber, Olga Naglo, Carla Pernpeintner, Siwei Zhang, Andreas Koeberle et al. British Journal of Cancer 2017 118: 43 - 51; November 07, 2017; 10.1038/bjc.2017.374   Abstract | Full Text Galectin-3 expression is prognostic in diffuse type gastric adenocarcinoma, confers aggressive phenotype, and can be targeted by YAP1/BET inhibitors Jaffer A Ajani, Jeannelyn S Estrella, Qiongrong Chen, Arlene M Correa, Lang Ma et al. British Journal of Cancer 2017 118: 52 - 61; November 14, 2017; 10.1038/bjc.2017.388   Abstract | Full Text Interferon regulatory factor 1 priming of tumour-derived exosomes enhances the antitumour immune response Mu-qing Yang, Qiang Du, Patrick R Varley, Julie Goswami, Zhihai Liang et al. British Journal of Cancer 2017 118: 62 - 71; November 07, 2017; 10.1038/bjc.2017.389   Abstract | Full Text Serum squamous cell carcinoma antigen as an early indicator of response during therapy of cervical cancer Stephanie Markovina, Songyan Wang, Lauren E Henke, Cliff J Luke, Stephen C Pak et al. British Journal of Cancer 2017 118: 72 - 78; November 07, 2017; 10.1038/bjc.2017.390   Abstract | Full Text Molecular Diagnostics Identification of a specific peptide binding to colon cancer cells from a phage-displayed peptide library Lidan Hou, Danxi Zhu, Yu Liang, Xiaohui Tian, Lei Li et al. British Journal of Cancer 2017 118: 79 - 87; October 24, 2017; 10.1038/bjc.2017.366   Abstract | Full Text Sox5 contributes to prostate cancer metastasis and is a master regulator of TGF-ß-induced epithelial mesenchymal transition through controlling Twist1 expression Jieping Hu, Jing Tian, Shimiao Zhu, Libin Sun, Jianpeng Yu et al. British Journal of Cancer 2017 118: 88 - 97; November 09, 2017; 10.1038/bjc.2017.372   Abstract | Full Text Prognostic impact and concordance of TERT promoter mutation and protein expression in matched primary and metastatic cutaneous melanoma   British Journal of Cancer 2017 118: 98 - 105; November 09, 2017; 10.1038/bjc.2017.384   Abstract | Full Text Genetics & Genomics Mechanisms of inactivation of the tumour suppressor gene RHOA in colorectal cancer Higinio Dopeso, Paulo Rodrigues, Josipa Bilic, Sarah Bazzocco, Fernando Cartón-García et al. British Journal of Cancer 2017 118: 106 - 116; December 05, 2017; 10.1038/bjc.2017.420   Abstract | Full Text Epidemiology Maternal diabetes and risk of childhood acute lymphoblastic leukaemia in the offspring   British Journal of Cancer 2017 118: 117 - 120; October 03, 2017; 10.1038/bjc.2017.351   Abstract | Full Text Family history of cancer in children and adolescents with germ cell tumours: a report from the Children's Oncology Group Jenny N Poynter, Michaela Richardson, Michelle Roesler, Mark Krailo, James F Amatruda et al. British Journal of Cancer 2017 118: 121 - 126; October 24, 2017; 10.1038/bjc.2017.358   Abstract | Full Text A systematic review and meta-analysis of the association between childhood infections and the risk of childhood acute lymphoblastic leukaemia Jeremiah Hwee, Christopher Tait, Lillian Sung, Jeffrey C Kwong, Rinku Sutradhar et al. British Journal of Cancer 2017 118: 127 - 137; October 24, 2017; 10.1038/bjc.2017.360   Abstract | Full Text High-grade cervical intraepithelial neoplasia in human papillomavirus self-sampling of screening non-attenders J U H Lam, K M Elfström, D M Ejegod, H Pedersen, C Rygaard et al. British Journal of Cancer 2017 118: 138 - 144; November 14, 2017; 10.1038/bjc.2017.371   Abstract | Full Text Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to British Journal of Cancer. In order to do so, please purchase a subscription. You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Springer Nature |One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Springer Nature's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW. © 2017 Macmillan Publishers Limited, part of Springer Nature. All Rights Reserved.